BMRN’s Q2 2026 consensus EPS estimate stands at $0.95, reflecting a 34% year-over-year decline, while revenue is expected to rise 13% to $932.04M.
BioMarin Pharmaceutical will report its Q2 2026 earnings on August 6 after market close. Analysts expect earnings per share of $0.95, a 34% drop from the same period last year, while revenue is projected to reach $932.04M, up 13% year-over-year.
The company has seen mixed performance over the past two years, with revenue growth offset by earnings volatility. The upcoming results will provide insight into BioMarin’s ability to sustain revenue expansion amid declining profitability.